Simmons Bank Sells 300 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Simmons Bank reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,997 shares of the medical equipment provider’s stock after selling 300 shares during the quarter. Simmons Bank’s holdings in Intuitive Surgical were worth $5,059,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ISRG. WCM Investment Management LLC purchased a new stake in Intuitive Surgical in the 4th quarter worth approximately $575,536,000. International Assets Investment Management LLC grew its position in shares of Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd increased its stake in shares of Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after purchasing an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Intuitive Surgical during the third quarter valued at approximately $178,667,000. Finally, Quadrature Capital Ltd grew its holdings in shares of Intuitive Surgical by 466.2% during the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after buying an additional 280,480 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ISRG shares. Mizuho raised their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Royal Bank of Canada upped their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Finally, Jefferies Financial Group boosted their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Insider Activity at Intuitive Surgical

In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,927 shares of company stock worth $57,064,459. 0.80% of the stock is currently owned by insiders.

Intuitive Surgical Price Performance

ISRG traded down $6.76 during midday trading on Wednesday, reaching $381.89. 577,803 shares of the company’s stock were exchanged, compared to its average volume of 1,596,291. The business’s 50-day moving average price is $385.34 and its 200 day moving average price is $351.97. The stock has a market capitalization of $135.46 billion, a PE ratio of 70.15, a P/E/G ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the company earned $1.00 EPS. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.